Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

Core Viewpoint - Psyence Biomedical Ltd. has decided to postpone the effective date of its previously announced reverse stock split of its common stock, which was initially set for January 20, 2026 [1][2]. Company Announcement - The Board of Directors had approved a reverse stock split at a ratio of 1-for-6.25, but after further internal consideration, the effectiveness of this split has been delayed to a later date [2]. - A subsequent press release will be issued, and required notifications will be filed with Nasdaq before establishing a new effective date for the reverse stock split [3]. Trading Information - Until a new effective date is established, the Company's common stock will continue to trade on the Nasdaq Capital Market under the ticker symbol "PBM" and its current CUSIP 74449F308 [3]. Company Overview - Psyence Biomedical Ltd. is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics, focusing on nature-derived psilocybin and ibogaine-based medicines [4]. - The company aims to address unmet mental health needs and is committed to developing safe, effective, and FDA-approved nature-derived psychedelic treatments for various mental health disorders [4].